Aim Immunotech Stock Price, News & Analysis

AIM ImmunoTech (NYSE American: AIM) published a new CEO Corner segment on December 10, 2025. CEO Thomas Equels discusses the unmet need in pancreatic cancer and the company’s lead therapy Ampligen (rintatolimod).

The segment summarizes Ampligen’s ongoing clinical evaluation in the DURIPANC Phase 1b/2 trial where it is being tested in combination with AstraZeneca’s Imfinzi (durvalumab). The CEO Corner video and comments are now available on the company website.

AIM ImmunoTech (NYSE American: AIM) CEO Thomas K. Equels will appear in a live, moderated "fireside" chat on the Virtual Investor Closing Bell Series on Thursday, December 4, 2025 at 4:00 PM ET. The discussion will focus on AIM's clinical and regulatory strategy for lead drug Ampligen, including the ongoing DURIPANC trial combining Ampligen with AstraZeneca's Imfinzi (durvalumab) for metastatic pancreatic cancer.

Equels will also review a completed Phase 2 trial with Merck evaluating Ampligen plus Keytruda (pembrolizumab) in advanced recurrent ovarian cancer; an abstract was presented at the 40th Annual SITC Meeting. Interested parties can submit questions in advance to aim@jtcir.com. A live webcast will stream on the company's Events page and a replay will be available two hours after the live presentation for 90 days.

AIM ImmunoTech (NYSE American: AIM) reported third quarter 2025 results and reiterated focus on advancing Ampligen as a combination therapy for pancreatic cancer.

Key items: positive mid-year safety and efficacy data from the ongoing DURIPANC trial with durvalumab; presentation of Phase 2 ovarian study data at SITC; granted a European patent for Long COVID compositions and a Japanese patent through 2039 for Ampligen plus checkpoint inhibitors; peer‑reviewed article in JITC; quarterly cash and investments of $2.4M; R&D of $607K and G&A of $1.8M; net loss $(3.3M) and an expected monthly burn of ~$550K.

AIM (NYSE American: AIM) detailed results from a completed Phase 2 trial of intraperitoneal cisplatin + IV pembrolizumab + intraperitoneal Ampligen presented at the 40th SITC Meeting on November 7, 2025. Of 27 enrolled patients (24 evaluable) with platinum-sensitive recurrent ovarian cancer, there were 5 complete responses and 7 partial responses, yielding an objective response rate (ORR) of 50%. The release cites prior pembrolizumab-only ORRs of 7.4% and 9.9% (Keynote-100) for context. The study is listed as ClinicalTrials.gov NCT03734692. AIM also notes U.S., Japan and Netherlands patents on Ampligen combination oncology use, expiring in 2039.

AIM ImmunoTech (NYSE American: AIM) announced that data from a completed Phase 2 cisplatin-resistant advanced recurrent ovarian cancer study using Ampligen (rintatolimod) was accepted as a late‑breaking abstract for presentation at the 40th Annual SITC Meeting (November 5-9, 2025) in National Harbor, MD.

Poster details: Title: A Phase II Trial of Combination Locoregional Chemoimmunotherapy in Recurrent Platinum-Sensitive Ovarian Cancer Triggers a T Lymphotactic Response Correlating with Clinical Outcomes; Presenting author: Mackenzy M. Radolec, MD; Abstract #1343; Date: Friday, November 7, 2025; Location: Prince George ABC Exhibit Halls, Gaylord National Resort and Convention Center.

AIM (NYSE American: AIM) announced on Nov 3, 2025 that the European Patent Office granted European Patent No. 4,096,675 for "Compositions for Treating LONG COVID," covering compositions of AIM’s dsRNAs including Ampligen (rintatolimod) for use in treating Long COVID.

The release notes prior in vitro, preclinical and clinical evidence, cites decreased SARS‑CoV‑1 replication and >90% structural homology with SARS‑CoV‑2, and references positive topline results from the Phase 2 AMP‑518 study reporting Ampligen was generally well tolerated with efficacy signals for reducing post‑COVID fatigue.

AIM ImmunoTech (NYSE American: AIM) will participate at the 2025 Maxim Growth Summit in New York on October 22–23, 2025.

Company management will be available for in-person one-on-one meetings with qualified, registered investors, and the presentation slide deck is available on the company's Presentations page at aimimmuno.com. For the full summit agenda, visit the Maxim Growth Summit website.

AIM ImmunoTech (NYSE American: AIM) has secured a significant patent in Japan for its cancer therapy combining Ampligen® (Rintatolimod) with checkpoint inhibitors, valid through 2039. The patent covers multiple cancer types and strengthens AIM's position in the world's third-largest pharmaceutical market.

The broad patent claims encompass treatments for pancreatic, skin, colorectal, ovarian, melanoma, breast, head and neck, bladder, renal cell, and lung cancers. AIM holds similar patents in the U.S. (expires 2039) and Netherlands (expires 2039) for Ampligen combination therapies.

The company is currently conducting a Phase 2 trial with AstraZeneca, combining Ampligen with durvalumab for metastatic pancreatic cancer, showing promising survival results. Additionally, a Phase 2 study with Merck combining Ampligen with Keytruda for advanced recurrent ovarian cancer awaits final data reports.

AIM ImmunoTech (NYSE American: AIM) announced the publication of a significant peer-reviewed article in the Journal for ImmunoTherapy of Cancer. The research demonstrates a positive combination effect of AIM's drug Ampligen when used with interferon-alpha on tumor growth and patient survival.

The study reveals that systemic chemokine modulation can overcome PD-1 resistance in cold tumors, highlighting that intratumoral cytotoxic t-lymphocyte accumulation is the crucial factor in immune checkpoint inhibitor effectiveness. The findings suggest promising potential for tumor microenvironment reprogramming strategies in cancer treatment.